![Tony Kennedy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Tony Kennedy
Directeur Technique/Scientifique/R&D chez
F2G Ltd.
Profil
Tony Kennedy is currently the Chief Scientific & Development Officer at F2G Ltd. Prior to this, he worked as a Principal at Smithkline Beecham Plc, Head-Project Management at Roche Pharmaceuticals, Inc., and as a Member at Hoffmann-La Roche, Inc. He also served as Vice President-Development at Trigen Holdings AG from 2002 to 2009 and as Head-Development at Vantia Ltd. Dr. Kennedy holds a graduate and doctorate degree from the University of London and an undergraduate degree from the University of Surrey.
Postes actifs de Tony Kennedy
| Sociétés | Poste | Début |
|---|---|---|
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology Engages in research and development of novel drugs for life-threatening systemic fungal diseases treatment | Directeur Technique/Scientifique/R&D | 11/01/2010 |
Anciens postes connus de Tony Kennedy
| Sociétés | Poste | Fin |
|---|---|---|
Trigen Holdings AG
 Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Develops drugs focusing on thrombosis and vascular dysfunction | Corporate Officer/Principal | 15/12/2009 |
Smithkline Beecham Plc
 Smithkline Beecham Plc Pharmaceuticals: OtherHealth Technology Develops and manufactures pharmaceutical products | Corporate Officer/Principal | - |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions | Corporate Officer/Principal | - |
Roche Pharmaceuticals, Inc.
 Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research and development services | Corporate Officer/Principal | - |
Vantia Ltd.
 Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Provides molecule agonists of vasopressin receptors | Corporate Officer/Principal | - |
Formation de Tony Kennedy
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
23
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Smithkline Beecham Plc
Smithkline Beecham Plc Pharmaceuticals: OtherHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
Roche Pharmaceuticals, Inc.
Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research and development services | Commercial Services |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions | Health Technology |
University of London
 University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Develops drugs focusing on thrombosis and vascular dysfunction | Commercial Services |
University of Surrey
 University of Surrey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology Engages in research and development of novel drugs for life-threatening systemic fungal diseases treatment | Health Technology |
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Provides molecule agonists of vasopressin receptors | Commercial Services |
